“Increasing Adoption of Combination Therapies”
- Combination therapies are being actively investigated in clinical trials and clinical practice to achieve optimal clinical outcomes
- The rationale behind combination approaches is to increase treatment effectiveness, break resistance, and address the intricacies of how the immune system reacts against diseases
- For instance, in April 2024, the FDA approved the combination of N-803 with BCG for treating BCG-unresponsive non-muscle-invasive bladder cancer, based on the QUILT 3.032 clinical trial led by UCLA, which demonstrated enhanced survival and efficacy
- The combination of drugs for treating particular cancer diseases drives the immunotherapy drug market
- This combined approach expands the immunotherapy drugs market and provides clinicians with a more versatile toolkit for managing complex cancer cases
